{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:35:00Z","timestamp":1777905300858,"version":"3.51.4"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81673510"],"award-info":[{"award-number":["81673510"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703628"],"award-info":[{"award-number":["81703628"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U1608282"],"award-info":[{"award-number":["U1608282"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ejps.2018.06.033","type":"journal-article","created":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T07:25:14Z","timestamp":1530689114000},"page":"170-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Population pharmacokinetics of valproic acid in epileptic children: Effects of clinical and genetic factors"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2624-9192","authenticated-orcid":false,"given":"Shansen","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingjie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanyou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Limei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2018.06.033_bb0005","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s10928-005-0083-6","article-title":"Inherent correlation between dose and clearance in therapeutic drug monitoring settings: possible misinterpretation in population pharmacokinetic analyses","volume":"32","author":"Ahn","year":"2005","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2018.06.033_bb0010","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1212\/WNL.52.4.889-a","article-title":"Treatment of absence status with intravenous valproate","volume":"52","author":"Alehan","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.ejps.2018.06.033_bb0015","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/bja\/aen248","article-title":"Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial","volume":"101","author":"Anand","year":"2008","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.ejps.2018.06.033_bb0020","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/00003088-199733050-00001","article-title":"Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients","volume":"33","author":"Anderson","year":"1997","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2018.06.033_bb0025","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2125.2006.02725.x","article-title":"Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance","volume":"63","author":"Anderson","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2018.06.033_bb0030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/dmd.108.022426","article-title":"Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10","volume":"37","author":"Argikar","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2018.06.033_bb0035","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/clpt.1985.116","article-title":"Valproic acid clearance: unbound fraction and diurnal variation in young and elderly adults","volume":"37","author":"Bauer","year":"1985","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2018.06.033_bb0040","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/FTD.0b013e31811f3296","article-title":"Population pharmacokinetics of valproic acid concentrations in elderly nursing home residents","volume":"29","author":"Birnbaum","year":"2007","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2018.06.033_bb0045","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.bcp.2010.04.034","article-title":"Functions and transcriptional regulation of adult human hepatic UDP-glucuronosyl-transferases (UGTs): mechanisms responsible for interindividual variation of UGT levels","volume":"80","author":"Bock","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejps.2018.06.033_bb0050","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/j.1552-4604.1995.tb04020.x","article-title":"A model for estimating individualized valproate clearance values in children","volume":"35","author":"Botha","year":"1995","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2018.06.033_bb0055","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJM199601183340308","article-title":"Antiepileptic drugs","volume":"334","author":"Brodie","year":"1996","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ejps.2018.06.033_bb0060","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/epi.13011","article-title":"Clinical significance of CYP2C9-status guided valproic acid therapy in children","volume":"56","author":"Budi","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2018.06.033_bb0065","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1054-3589(08)60758-9","article-title":"The structure and function of the UDP-glucuronosyltransferase gene family","volume":"42","author":"Burchell","year":"1998","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.ejps.2018.06.033_bb0070","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40262-016-0456-6","article-title":"Genetic polymorphisms affecting the pharmacokinetics of antiretroviral drugs","volume":"56","author":"Calcagno","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2018.06.033_bb0075","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/0091270002239821","article-title":"Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children","volume":"43","author":"Capparelli","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2018.06.033_bb0080","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/JCP.0b013e3181f03f50","article-title":"C825T polymorphism of the GNB3 gene on valproate-related metabolic abnormalities in bipolar disorder patients","volume":"30","author":"Chang","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejps.2018.06.033_bb0085","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2217\/pgs.12.78","article-title":"Functional impact and prevalence of polymorphisms involved in the hepatic glucuronidation of valproic acid","volume":"13","author":"Chatzistefanidis","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ejps.2018.06.033_bb0090","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00228-012-1277-7","article-title":"Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients","volume":"68","author":"Chu","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2018.06.033_bb0095","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/bdd.636","article-title":"Population pharmacokinetics of valproate in Mexican children with epilepsy","volume":"29","author":"Correa","year":"2008","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2018.06.033_bb0100","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40262-014-0212-8","article-title":"A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation","volume":"54","author":"Ding","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2018.06.033_bb0105","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00228-003-0699-7","article-title":"Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients","volume":"59","author":"EL","year":"2004","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2018.06.033_bb0110","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S0006-2952(03)00076-5","article-title":"The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases","volume":"65","author":"Ethell","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejps.2018.06.033_bb0115","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","article-title":"Valproic acid pathway: pharmacokinetics and pharmacodynamics","volume":"23","author":"Ghodke-Puranik","year":"2013","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.ejps.2018.06.033_bb0120","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/01.fpc.0000114754.08559.27","article-title":"Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver","volume":"14","author":"Girard","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.ejps.2018.06.033_bb0125","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1124\/dmd.106.009787","article-title":"The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver","volume":"34","author":"Girard","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2018.06.033_bb0130","first-page":"507","article-title":"Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3","volume":"26","author":"Green","year":"1998","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2018.06.033_bb0135","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/JCP.0b013e31819359be","article-title":"Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication","volume":"29","author":"Gregoor","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejps.2018.06.033_bb0140","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2217\/pgs.11.40","article-title":"Polymorphisms of the LEP, LEPR and HTR2C gene: obesity and BMI change in patients using antipsychotic medication in a naturalistic setting","volume":"12","author":"Gregoor","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ejps.2018.06.033_bb0145","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2133\/dmpk.DMPK-11-NT-144","article-title":"Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy","volume":"27","author":"Guo","year":"2012","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejps.2018.06.033_bb0150","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.seizure.2011.01.008","article-title":"Lack of association of ABCB1 and PXR polymorphisms with response to treatment in epilepsy","volume":"20","author":"Haerian","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.ejps.2018.06.033_bb0155","first-page":"335","article-title":"Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes","volume":"3","author":"Ho","year":"2003","journal-title":"Pharm. J."},{"key":"10.1016\/j.ejps.2018.06.033_bb0160","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/jps.23574","article-title":"A pharmacokinetic standard for babies and adults","volume":"102","author":"Holford","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.06.033_bb0165","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2217\/pgs.11.64","article-title":"Association of genetic variants in six candidate genes with valproic acid therapy optimization","volume":"12","author":"Hung","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ejps.2018.06.033_bb0170","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/FTD.0000000000000012","article-title":"Influence of uridine diphosphate glucuronosyltransferase 2B7-161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients","volume":"36","author":"Inoue","year":"2014","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2018.06.033_bb0175","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0304-4165(90)90079-C","article-title":"The enzymatic basis for the metabolism and inhibitory effects of valproic acid: dehydrogenation of valproyl-CoA by 2-methyl-branched-chain acyl-CoA dehydrogenase","volume":"1034","author":"Ito","year":"1990","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejps.2018.06.033_bb0180","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4103\/0028-3886.152631","article-title":"Prevalence of UGT1A6 polymorphisms in children with epilepsy on valproate monotherapy","volume":"63","author":"Jain","year":"2015","journal-title":"Neurol. India"},{"key":"10.1016\/j.ejps.2018.06.033_bb0185","doi-asserted-by":"crossref","first-page":"767","DOI":"10.5414\/CPP48767","article-title":"Factors influencing valproate pharmacokinetics in children and adults","volume":"48","author":"Jankovic","year":"2010","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2018.06.033_bb0190","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1111\/j.1745-7254.2007.00704.x","article-title":"Population pharmacokinetics of valproate in Chinese children with epilepsy","volume":"28","author":"Jiang","year":"2007","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejps.2018.06.033_bb0195","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00228-009-0712-x","article-title":"Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling","volume":"65","author":"Jiang","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2018.06.033_bb0200","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00007691-200306000-00005","article-title":"Population pharmacokinetics of carbamazepine in Chinese epilepsy patients","volume":"25","author":"Jiao","year":"2003","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2018.06.033_bb0205","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.canlet.2005.06.051","article-title":"Implications of genetic polymorphisms in drug transporters for pharmacotherapy","volume":"234","author":"Kerb","year":"2006","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejps.2018.06.033_bb0210","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2165\/00003088-200948060-00003","article-title":"Morphine glucuronidation in preterm neonates, infants and children younger than 3\u202fyears","volume":"48","author":"Knibbe","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2018.06.033_bb0215","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00007691-199202000-00009","article-title":"Binding parameters of valproic acid to serum protein in healthy adults at steady state","volume":"14","author":"Kodama","year":"1992","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2018.06.033_bb0220","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1124\/jpet.104.081968","article-title":"UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S)","volume":"313","author":"Krishnaswamy","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2018.06.033_bb0225","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2174\/1389200054633880","article-title":"Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics","volume":"6","author":"Lamba","year":"2005","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejps.2018.06.033_bb0230","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejmech.2014.03.048","article-title":"Therapeutic potential of leptin receptor modulators","volume":"78","author":"Leggio","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.033_bb0235","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.eplepsyres.2014.03.019","article-title":"The ABCB1-C3435T polymorphism likely acts as a risk factor for resistance to antiepileptic drugs","volume":"108","author":"Li","year":"2014","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejps.2018.06.033_bb0240","doi-asserted-by":"crossref","first-page":"v21","DOI":"10.1093\/ijnp\/pyv021","article-title":"Association of LEPR and ANKK1 gene polymorphisms with weight gain in epilepsy patients receiving valproic acid","volume":"18","author":"Li","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejps.2018.06.033_bb0245","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/1753-0407.12553","article-title":"Effect of AMP-activated protein kinase subunit alpha 2 (PRKAA2) genetic polymorphisms on susceptibility to type 2 diabetes mellitus and diabetic nephropathy in a Chinese population","volume":"10","author":"Li","year":"2018","journal-title":"J. Diabetes"},{"key":"10.1016\/j.ejps.2018.06.033_bb0250","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/FTD.0000000000000100","article-title":"Population pharmacokinetics of valproic acid in adult Chinese epileptic patients and its application in an individualized dosage regimen","volume":"37","author":"Lin","year":"2015","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2018.06.033_bb0255","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.1093\/hmg\/ddu268","article-title":"Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liver","volume":"23","author":"Liu","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejps.2018.06.033_bb0260","first-page":"766","article-title":"Effect of UGT2B7 genetic variants on serum valproic acid concentration","volume":"38","author":"Ma","year":"2013","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"10.1016\/j.ejps.2018.06.033_bb0265","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00008571-199708000-00001","article-title":"The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence","volume":"7","author":"Mackenzie","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.ejps.2018.06.033_bb0270","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2125.2006.02622.x","article-title":"Prediction of drug clearance in children from adults: a comparison of several allometric methods","volume":"61","author":"Mahmood","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2018.06.033_bb0275","doi-asserted-by":"crossref","first-page":"e141266","DOI":"10.1371\/journal.pone.0141266","article-title":"Determination of the optimal concentration of valproic acid in patients with epilepsy: a population pharmacokinetic-pharmacodynamic analysis","volume":"10","author":"Nakashima","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejps.2018.06.033_bb0280","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.seizure.2012.04.014","article-title":"Trends in antiepileptic drug utilisation in UK primary care 1993\u20132008: cohort study using the General Practice Research Database","volume":"21","author":"Nicholas","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.ejps.2018.06.033_bb0285","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00228-016-2137-7","article-title":"Hepatic expression of transcription factors affecting developmental regulation of UGT1A1 in the Han Chinese population","volume":"73","author":"Nie","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2018.06.033_bb0290","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.earlhumdev.2005.06.001","article-title":"Pharmacokinetics of antivirals in neonate","volume":"81","author":"Pacifici","year":"2005","journal-title":"Early Hum. Dev."},{"key":"10.1016\/j.ejps.2018.06.033_bb0295","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1528-1157.2002.13001.x","article-title":"The importance of drug interactions in epilepsy therapy","volume":"43","author":"Patsalos","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2018.06.033_bb0300","doi-asserted-by":"crossref","first-page":"T9","DOI":"10.1530\/JOE-14-0264","article-title":"20\u202fyears of leptin: insights into signaling assemblies of the leptin receptor","volume":"223","author":"Peelman","year":"2014","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.ejps.2018.06.033_bb0305","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2165\/11319350-000000000-00000","article-title":"Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model","volume":"49","author":"Peeters","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2018.06.033_bb0310","doi-asserted-by":"crossref","first-page":"101178","DOI":"10.11131\/2015\/101178","article-title":"Nuclear receptors in drug metabolism, drug response and drug interactions","volume":"2","author":"Prakash","year":"2015","journal-title":"Nucl. Recept. Res."},{"key":"10.1016\/j.ejps.2018.06.033_bb0315","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1128\/AAC.00781-10","article-title":"Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance","volume":"54","author":"Schipani","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2018.06.033_bb0320","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1365-2710.1999.00202.x","article-title":"Valproate population pharmacokinetics in children","volume":"24","author":"Serrano","year":"1999","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ejps.2018.06.033_bb0325","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00228-016-2087-0","article-title":"Impact of age, gender and CYP2C9\/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data","volume":"72","author":"Smith","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2018.06.033_bb0330","first-page":"2033","article-title":"Effect of UGT1A6 genetic polymorphisms on the metabolism of sodium valproate","volume":"87","author":"Sun","year":"2007","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.ejps.2018.06.033_bb0335","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.eplepsyres.2015.04.015","article-title":"The influence of UGT2B7 genotype on valproic acid pharmacokinetics in Chinese epilepsy patients","volume":"114","author":"Sun","year":"2015","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejps.2018.06.033_bb0340","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.2042-7158.2011.01282.x","article-title":"No effect of co-administered antiepileptic drugs on in-vivo protein binding parameters of valproic acid in patients with epilepsy","volume":"63","author":"Suzuki","year":"2011","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2018.06.033_bb0345","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/QAI.0b013e3181f52f0c","article-title":"Nuclear receptor-mediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans","volume":"55","author":"Svard","year":"2010","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.ejps.2018.06.033_bb0350","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.clineuro.2010.01.002","article-title":"The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients","volume":"112","author":"Tan","year":"2010","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.ejps.2018.06.033_bb0355","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11033-007-9206-z","article-title":"Association of MDR1 C3435T polymorphism with bipolar disorder in patients treated with valproic acid","volume":"36","author":"Turgut","year":"2009","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ejps.2018.06.033_bb0360","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2710.2008.00885.x","article-title":"Characterization of non-linear relationship between total and unbound serum concentrations of valproic acid in epileptic children","volume":"33","author":"Ueshima","year":"2008","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ejps.2018.06.033_bb0365","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1158\/1078-0432.CCR-09-0494","article-title":"Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes","volume":"15","author":"Voso","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2018.06.033_bb0370","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ejps.2009.09.017","article-title":"The influence of drug-drug interaction and patients' characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling","volume":"38","author":"Vucicevic","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.06.033_bb0375","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jchemneu.2014.09.002","article-title":"Leptin and its receptors","volume":"61-62","author":"Wada","year":"2014","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.ejps.2018.06.033_bb0380","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2165\/00003088-200342150-00003","article-title":"Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes","volume":"42","author":"Wang","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2018.06.033_bb0385","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/FTD.0000000000000271","article-title":"Effects of UGT2B7 genetic polymorphisms on serum concentrations of valproic acid in chinese children with epilepsy comedicated with lamotrigine","volume":"38","author":"Wang","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2018.06.033_bb0390","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00228-017-2395-z","article-title":"Effect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis","volume":"74","author":"Wang","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2018.06.033_bb0395","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1600-0897.2009.00799.x","article-title":"Original article: leptin gene (TTTC)n microsatellite polymorphism as well as leptin receptor R223Q and PPAR\u03b32 P12A substitutions are not associated with hypertensive disorders in pregnancy","volume":"63","author":"Wiedemann","year":"2010","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.ejps.2018.06.033_bb0400","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrd753","article-title":"PXR, CAR and drug metabolism","volume":"1","author":"Willson","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejps.2018.06.033_bb0405","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/jac\/dkr272","article-title":"Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens","volume":"66","author":"Wyen","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2018.06.033_bb0410","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/FTD.0000000000000431","article-title":"Development of a simple and rapid method to measure free fraction of valproic acid in plasma using ultrafiltration and ultra high performance liquid chromatography-mass spectroscopy: application to therapeutic drug monitoring","volume":"39","author":"Xu","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2018.06.033_bb0415","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2217\/pgs.10.22","article-title":"Pharmacogenomics of membrane transporters: past, present and future","volume":"11","author":"Yee","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ejps.2018.06.033_bb0420","doi-asserted-by":"crossref","first-page":"254","DOI":"10.5808\/GI.2013.11.4.254","article-title":"Genetic variations of ABCC2 gene associated with adverse drug reactions to valproic acid in korean epileptic patients","volume":"11","author":"Yi","year":"2013","journal-title":"Genome Inform."},{"key":"10.1016\/j.ejps.2018.06.033_bb0425","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1210\/jcem.86.9.7842","article-title":"The Q223R polymorphism of the leptin receptor gene is significantly associated with obesity and predicts a small percentage of body weight and body composition variability","volume":"86","author":"Yiannakouris","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejps.2018.06.033_bb0430","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00003088-198815060-00002","article-title":"Clinical pharmacokinetics of valproic acid\u20141988","volume":"15","author":"Zaccara","year":"1988","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2018.06.033_bb0435","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.dmpk.2014.10.008","article-title":"Effect of CAR polymorphism on the pharmacokinetics of artemisinin in healthy Chinese subjects","volume":"30","author":"Zang","year":"2015","journal-title":"Drug Metab. Pharmacokinet."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098718302975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098718302975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T22:40:28Z","timestamp":1534804828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098718302975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":87,"alternative-id":["S0928098718302975"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2018.06.033","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetics of valproic acid in epileptic children: Effects of clinical and genetic factors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2018.06.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}